1,886
Views
5
CrossRef citations to date
0
Altmetric
Review

Progress and application of epitranscriptomic m6A modification in gastric cancer

& ORCID Icon
Pages 885-896 | Received 18 Mar 2022, Accepted 27 Jun 2022, Published online: 07 Jul 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Tony Gutschner. (2023) RNA therapeutics. RNA Biology 0:0, pages 1-2.
Read now

Articles from other publishers (4)

Lianhui Sun, Yuan Zhang, Boyu Yang, Sijun Sun, Pengshan Zhang, Zai Luo, Tingting Feng, Zelin Cui, Ting Zhu, Yuming Li, Zhengjun Qiu, Guangjian Fan & Chen Huang. (2023) Lactylation of METTL16 promotes cuproptosis via m6A-modification on FDX1 mRNA in gastric cancer. Nature Communications 14:1.
Crossref
Hong Meng, Jing Li, Huapeng Sun, Yanxin Lin, Haisheng Xu & Na Zhang. (2023) The transcription factor ATF2 promotes gastric cancer progression by activating the METTL3/cyclin D1 pathway. Drug Development Research 84:6, pages 1325-1334.
Crossref
Yuheng Lu, Hongbo Zhang, Haoyan Pan, Zhicheng Zhang, Hua Zeng, Haoyu Xie, Jianbin Yin, Wen Tang, Rengui Lin, Chun Zeng & Daozhang Cai. (2023) Expression pattern analysis of m6A regulators reveals IGF2BP3 as a key modulator in osteoarthritis synovial macrophages. Journal of Translational Medicine 21:1.
Crossref
Gaofeng Li, Qiru Fu, Cong Liu, Yuxi Peng, Jun Gong, Shilan Li, Yan Huang & Haiyuan Zhang. (2022) The regulatory role of N6-methyladenosine RNA modification in gastric cancer: Molecular mechanisms and potential therapeutic targets. Frontiers in Oncology 12.
Crossref